NCT03933670View on ClinicalTrials.gov

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients with Prostate Cancer on Active Surveillance

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

March 31, 2026

Study Completion Date

October 31, 2026

Conditions
Prostate AdenocarcinomaProstate Cancer
Interventions
DRUG

Hyperpolarized Carbon C 13 Pyruvate

Given IV

PROCEDURE

Magnetic Resonance Spectroscopic Imaging

Undergo MRSI

PROCEDURE

MRI Ultrasound Fusion Guided Biopsy

Undergo MR/US fusion-guided prostate biopsy

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

lead

University of California, San Francisco

OTHER